About Complement C1q tumor necrosis factor-related protein 7
Complement C1q tumor necrosis factor-related protein 7 (C1QTNF7) is a protein
from Homo sapiens identified by UniProt accession
Q9BXJ2, 289 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Complement C1q tumor necrosis factor-related protein 7 |
|---|
| UniProt accession | Q9BXJ2 |
|---|
| Gene | C1QTNF7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 289 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (64)
Diseases linked to this target (Open Targets).
- BMI-adjusted waist-hip ratio · score 0.43
- pulse pressure measurement · score 0.41
- waist-hip ratio · score 0.40
- conduct disorder · score 0.33
- leukocyte count · score 0.33
- Hernia · score 0.26
- periodontal measurement · score 0.24
- self reported educational attainment · score 0.24
- smoking status measurement · score 0.23
- insulin resistance · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BXJ2-F1 | alphafold | PREDICTED | 73.61 | — |
Amino-acid sequence (289 residues)
MFVLLYVTSF AICASGQPRG NQLKGENYSP RYICSIPGLP GPPGPPGANG SPGPHGRIGL PGRDGRDGRK GEKGEKGTAG LRGKTGPLGL AGEKGDQGET GKKGPIGPEG EKGEVGPIGP PGPKGDRGEQ GDPGLPGVCR CGSIVLKSAF SVGITTSYPE ERLPIIFNKV LFNEGEHYNP ATGKFICAFP GIYYFSYDIT LANKHLAIGL VHNGQYRIKT FDANTGNHDV ASGSTVIYLQ PEDEVWLEIF FTDQNGLFSD PGWADSLFSG FLLYVDTDYL DSISEDDEL
Explore Complement C1q tumor necrosis factor-related protein 7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets